← Back
Data updated: Jun 28, 2026
BRIGHAM WOMENS HOSP
Generics Pharmaceuticals
BRIGHAM WOMENS HOSP is a generic drug manufacturer with 1 FDA-approved products.
2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
BRIGHAM WOMENS HOSP's Key Drugs
BRIGHAM WOMENS HOSP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
BRIGHAM WOMENS HOSP's Recent FDA Approvals
New NDA/BLA approvals for BRIGHAM WOMENS HOSP over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
BRIGHAM WOMENS HOSP's Therapeutic Areas
Disease areas where BRIGHAM WOMENS HOSP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
BRIGHAM WOMENS HOSP Pipeline Snapshot
Active clinical trials for BRIGHAM WOMENS HOSP across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-10-30
- Latest
- 2019-08-14
- Applications
- 1